Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents

无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测

基本信息

项目摘要

PROJECT SUMMARY Ischemic heart disease (IHD) is the leading cause of death in the United States. It emanates from narrowing of coronary arteries (CAD) and/or development of microvascular dysfunction culminating in myocardial ischemia – a condition where the oxygen demand of the myocardium is far in excess of the available supply. IHD accounts for more than 1 in 3 deaths and >1 million hospitalizations each year in the US. The extent and severity of myocardial ischemia has been shown to provide incremental prognostic value over standard clinical variables across the spectrum of presentation of patients with IHD. Long-established (SPECT or PET) and more recently established (e.g., first pass-perfusion MRI) methods are routinely used to gather this information. In spite of their capabilities, these methods have key limitations – they expose the patients to either ionizing radiation or exogenous contrast agents, which carry risks to the patients. This is particularly a critical problem in at least half a million patients with end-stage renal disease (ESRD) in the US. In ESRD patients, annual ischemia testing is needed since the risk of cardiovascular mortality is > 10-fold greater than in the general population. Hence there is an unmet and growing need for safe and reliable assessment of myocardial ischemia in all patients, and is most pressing in ESRD patients, whose prevalence in the US is on the rise. Blood-Oxygen-Level-Dependent (BOLD) Cardiac MRI (CMR) is a potential alternative to standard clinical methods since it is free of ionizing radiation and exogenous contrast media. It also has the capability to provide physiological insight into the disease based on measurements of impaired oxygen supply, and not from surrogate metrics (wall motion, ECG changes, or contrast kinetics). Over the past two decades, the technical capabilities of BOLD CMR have led to clinical testing. However, limitations in reliability (sensitivity, specificity and accuracy) remain a major impediment for widespread clinical use of BOLD CMR. To overcome the reliability limitations of BOLD CMR, in a previous R01 funding (2013 to 2017), we hypothesized that repeat stimulations of the heart, analogous to brain activation studies using BOLD MRI (brain fMRI), could improve the reliability of BOLD CMR. Subsequently, we went onto demonstrate that (i) a targeted change in arterial partial pressure of CO2 (PaCO2) can be a potent non-invasive vasoactive stimulus; and a (ii) high-resolution, whole heart BOLD CMR at 3T with repeat PaCO2 stimulation of the heart, when combined with a statistical framework, can reliably detect BOLD signal changes in large, healthy, animals. To successfully translate the promising impact of this BOLD CMR approach into the clinical arena, further advances and validation will be required. This proposal aims to continue the successful advancement of this BOLD CMR approach towards clinical feasibility so that it can enable a truly noninvasive and cost-effective ischemia testing that is free of ionizing radiation, exogenous contrast agents, intravenous pharmacological agents or even needles. Thus, this proposal is a critical step towards advancing the care of a large segment of IHD patients in the US.
项目摘要 缺血性心脏病(IHD)是美国的主要死因。它源于缩小 冠状动脉(CAD)和/或微血管功能障碍的发展,最终导致心肌缺血 - 心肌的氧需求远远超过可用供应的情况。IHD 在美国,每年超过三分之一的死亡和超过一百万的住院治疗。的程度和 心肌缺血的严重程度已经显示出提供超过标准临床诊断的增量预后价值, IHD患者表现谱中的变量。长期建立的(SPECT或PET)和 最近建立的(例如,第一次通过灌注MRI)方法常规地用于收集该信息。 尽管它们的能力,这些方法有关键的限制-他们暴露于患者或电离 放射或外源性造影剂,这会给患者带来风险。这是一个特别关键的问题 在美国至少有50万终末期肾病(ESRD)患者。在ESRD患者中,每年 由于心血管死亡的风险比一般情况高10倍以上,因此需要进行缺血试验。 人口因此,对安全可靠地评估心肌梗死的需要未得到满足,并且不断增长。 缺血在所有患者中是最紧迫的,并且在ESRD患者中是最紧迫的,其在美国的患病率正在上升。 血氧水平依赖性(BOLD)心脏MRI(CMR)是标准临床MRI的潜在替代方案, 方法,因为它不含电离辐射和外源性造影剂。它也有能力提供 根据受损的氧气供应的测量,而不是从生理上了解疾病, 替代指标(室壁运动、ECG变化或造影动力学)。在过去的二十年里,技术 BOLD CMR的能力已经导致了临床测试。然而,可靠性(灵敏度、特异性)的局限性 和准确性)仍然是BOLD CMR广泛临床应用的主要障碍。克服 BOLD CMR的可靠性限制,在之前的R01资助(2013年至2017年)中,我们假设重复 心脏的刺激,类似于使用BOLD MRI(脑功能磁共振成像)的大脑激活研究,可以改善 BOLD CMR的可靠性。随后,我们继续证明(i)动脉的靶向变化 CO2分压(PaCO2)可以是有效的非侵入性血管活性刺激;和(ii)高分辨率, 3T下的全心脏BOLD CMR,心脏重复PaCO2刺激,结合统计学 该框架可以可靠地检测大型健康动物的BOLD信号变化。要成功翻译 这种BOLD CMR方法对临床竞技场的影响是有希望的,进一步的进展和验证将是 必需的.本提案旨在继续成功推进BOLD CMR方法, 临床可行性,以便能够进行真正无创且具有成本效益的缺血测试,并且无需 电离辐射、外源性造影剂、静脉内药物制剂或甚至针头。因此,这 该提案是推进美国大部分IHD患者护理的关键一步。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Disentangle, Align and Fuse for Multimodal and Semi-Supervised Image Segmentation.
  • DOI:
    10.1109/tmi.2020.3036584
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    10.6
  • 作者:
    Chartsias A;Papanastasiou G;Wang C;Semple S;Newby DE;Dharmakumar R;Tsaftaris SA
  • 通讯作者:
    Tsaftaris SA
Artificial Intelligence for Contrast-Free MRI: Scar Assessment in Myocardial Infarction Using Deep Learning-Based Virtual Native Enhancement.
  • DOI:
    10.1161/circulationaha.122.060137
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
    37.8
  • 作者:
    Zhang Q;Burrage MK;Shanmuganathan M;Gonzales RA;Lukaschuk E;Thomas KE;Mills R;Leal Pelado J;Nikolaidou C;Popescu IA;Lee YP;Zhang X;Dharmakumar R;Myerson SG;Rider O;Oxford Acute Myocardial Infarction (OxAMI) Study;Channon KM;Neubauer S;Piechnik SK;Ferreira VM
  • 通讯作者:
    Ferreira VM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rohan Dharmakumar其他文献

Rohan Dharmakumar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rohan Dharmakumar', 18)}}的其他基金

Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
  • 批准号:
    10359807
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
  • 批准号:
    9981378
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
  • 批准号:
    10630055
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
  • 批准号:
    9887771
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
  • 批准号:
    10201743
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
  • 批准号:
    10655692
  • 财政年份:
    2020
  • 资助金额:
    $ 67.1万
  • 项目类别:
Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart Failure
开发 MRI 引导的梗死后慢性心力衰竭疾病缓解疗法
  • 批准号:
    9981537
  • 财政年份:
    2017
  • 资助金额:
    $ 67.1万
  • 项目类别:
Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart Failure
开发 MRI 引导的梗死后慢性心力衰竭疾病缓解疗法
  • 批准号:
    9756228
  • 财政年份:
    2017
  • 资助金额:
    $ 67.1万
  • 项目类别:
4D SSFP MRI for Detecting Functionally Important Coronary Artery Stenosis at Rest
4D SSFP MRI 用于检测静息时具有重要功能的冠状动脉狭窄
  • 批准号:
    7837299
  • 财政年份:
    2009
  • 资助金额:
    $ 67.1万
  • 项目类别:
4D SSFP MRI for Detecting Functionally Important Coronary Artery Stenosis at Rest
4D SSFP MRI 用于检测静息时具有重要功能的冠状动脉狭窄
  • 批准号:
    8055423
  • 财政年份:
    2008
  • 资助金额:
    $ 67.1万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.1万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了